Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $2.26, but opened at $2.34. Autolus Therapeutics shares last traded at $2.22, with a volume of 209,357 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, December 5th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Stock Down 2.2 %

The firm has a market cap of $588.07 million, a P/E ratio of -1.83 and a beta of 1.98. The business's 50 day moving average is $3.18 and its 200-day moving average is $3.71.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) EPS. As a group, equities analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC raised its position in shares of Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock worth $152,000 after purchasing an additional 3,740 shares during the period. Wealth Effects LLC lifted its stake in Autolus Therapeutics by 19.5% in the second quarter. Wealth Effects LLC now owns 49,000 shares of the company's stock valued at $171,000 after buying an additional 8,000 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after acquiring an additional 9,000 shares during the period. State Street Corp increased its holdings in shares of Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. Finally, ProShare Advisors LLC acquired a new position in Autolus Therapeutics during the 2nd quarter valued at about $43,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.